Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.185 USD | -2.02% |
|
+34.36% | +43.14% |
16/07 | FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin | MT |
16/07 | FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.14% | 806M | |
+18.22% | 126B | |
+23.34% | 118B | |
+23.52% | 27.87B | |
-18.20% | 20.95B | |
-15.13% | 16.92B | |
-14.68% | 16.18B | |
+9.11% | 14.84B | |
-46.10% | 14.79B | |
+52.49% | 14.08B |
- Stock Market
- Equities
- LXRX Stock
- News Lexicon Pharmaceuticals, Inc.
- Transcript : Lexicon Pharmaceuticals, Inc. - Special Call